Advanced Search

Orthopedic Coding Alert

Reader Question:

Synvisc for Shoulders

Published on Thu Aug 01, 2002

Question: Is there any way that Medicare will reimburse us for a shoulder injection using Synvisc? Minnesota Subscriber

Answer: No. Because the U.S. Food and Drug Administration approved Synvisc (J7320, Hylan G-F 20, 16 mg, for intra-articular injection) only for patients with osteoarthritis of the knee (715.16, 715.26, 715.36 and 715.96), Medicare will not cover its use for any other diagnoses or conditions. Some private payers reimburse for the medication when Synvisc is injected into the shoulder, but most will not pay for the administration (20610*, Arthrocentesis, aspiration and/or injection; major joint or bursa [e.g., shoulder, hip, knee joint, subacromial bursa]).

Don't assume, however, that you cannot report an outpatient consultation code when the ED physician calls your orthopedist to evaluate a patient. Each encounter must be evaluated individually.  
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Orthopedic Coding Alert

View All